India, Aug. 28 -- This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
Key developments included FDA approvals for Gilead's Bixlenvo, Roivant's LISRAYA, and Johnson & Johnson's IMAAVY, while Biohaven, Celularity, and Lilly advanced partnerships to expand their pipelines and commercial capabilities. Clinical readouts spanned therapeutic areas including eosinophilic esophagitis and biliary tract cancer
Let's take a closer look at the details.
FDA Approvals
Gilead's Bixlenvo Wins FDA Nod in HIV
Gilead Sciences, Inc. (GILD) secured FDA approval for Bixlenvo (bictegravir 75...